Search Results
Nov 05, 2025, 08:15 ET Introducing the Future of K-12 Assessment: The IXL LevelUp™ Diagnostic
Currently used by 17 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 100 languages, IXL's end-to-end
More news about: IXL Learning
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
NCT06487624) is a multi-regional, multi-center, open-label, dose-finding, first-in-human trial evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical efficacy of HCB301 in patients with advanced solid tumors or relapsed and refractory classical Hodgkin
More news about: HanchorBio Inc.
Nov 04, 2025, 19:00 ET Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
level of attention in recent years, and we have developed an innovative TACI/BCMA fusion protein (IBI3034) with excellent developability, function and PK profile. Among them, IBI3011 can be administered subcutaneously, and IBI3034 allows for long-interval dosing. Together, we hope that these differentiated
More news about: Innovent Biologics
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration DA-1726 Achieves Superior
More news about: MetaVia Inc.
Nov 01, 2025, 09:00 ET Bigo Live Launches "Grateful Streams" Campaign to Support Union Station Homeless Services This November
"Giving Battles" (PK Sessions): Creator challenges that spotlight the cause and rally more contributions.Top hosts across the platform are streaming in exciting PK battles where their communities share virtual gifts to give back. Each virtual gift sent during these PK battles will
More news about: Bigo Live
Oct 30, 2025, 09:00 ET Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting
storytelling. Looking ahead, Saama plans to expand its Figures-to-Text capabilities to support pharmacokinetic/pharmacodynamic (PK/PD) and exposure-response analyses, enhance cross-study insights through Agentic AI, and move toward a fully automated CSR generation pipeline.
More news about: Saama
Oct 30, 2025, 08:00 ET ChemDiv's Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer
potential. Rapid synthesis + learn cycles: Parallel synthesis and micro‑scale PK accelerate SAR hypotheses; "success criteria" dashboards track mutant coverage, WT‑sparing index, and developability in each sprint.
More news about: ChemDiv
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
from Phase III clinical trials in postmenopausal women with osteoporosis designed to evaluate the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), safety and immunogenicity of denosumab biosimilar to its reference product. [1] STOBOCLO and OSENVELT were introduced
More news about: Celltrion
Oct 29, 2025, 08:00 ET InSysBio to announce its collaboration with BeOne Medicines
The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody LIMASSOL, Cyprus, Oct.
More news about: InSysBio
Oct 29, 2025, 05:49 ET Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media Innovation for Industrialization at CPHI Frankfurt 2025
molecule design and optimization, antibody discovery and engineering, linker-payload screening and conjugation, developability assessment, pharmacology and PK/PD studies, and early-stage sample preparation. This integrated approach, extending to structural characterization and novel formulation development,
More news about: Thousand Oaks Biologics
Oct 28, 2025, 09:35 ET Telas comerciais LG impulsionam o varejo para temporada de vendas de fim de ano
era digital." Dentro da loja, a estratégia é reduzir o atrito e aprofundar o engajamento. O Kiosk de Autoatendimento (27KC3PK-C) agiliza pedidos e pagamentos, diminuindo as filas que são um dos principais motivos de abandono de compra em períodos de pico. Para criar ambientes
More news about: LG Electronics Brasil
Oct 28, 2025, 08:00 ET Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
and Sustained Clinical Cure. In the Phase 2 clinical trial (both trial segments), the Company also evaluated pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance,
More news about: Acurx Pharmaceuticals, Inc.
Oct 27, 2025, 16:03 ET BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
extensive body of evidence supporting VOXZOGO's health benefits beyond improving growth. As a follow-up to the encouraging PK data announced last quarter for BMN 333, BioMarin's long-acting C-type natriuretic peptide, the company plans to initiate dosing of children with achondroplasia
More news about: BioMarin Pharmaceutical Inc.
Oct 27, 2025, 08:01 ET All Aboard! Yankee Candle® Spark Holiday Wonder with a New Limited Edition Collection Inspired by The Polar Express
Mini Filled Votive Giftset (3ct): $11.99 7.5oz Tumbler Giftset (3pk): $49.99 6.2oz Tumbler Giftset (2ct): $69.99
More news about: Newell Brands
Oct 26, 2025, 21:00 ET Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
therapeutic potential in the treatment of autoimmune diseases. However, the clinical development of TCEs has been limited by suboptimal pharmacokinetics (PK), incomplete B cell depletion, and toxicity associated with CRS. To address these challenges, Antengene leveraged its proprietary AnTenGagerTM
More news about: Antengene Corporation Limited
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
encouraged by the excellent safety profile and initial responses observed in heavily pretreated patients. These monotherapy data establish safety, PK/PD, and early activity, providing the foundation for our ongoing combination trials testing HCB101 layered onto standard backbones in multiple tumor types.
More news about: HanchorBio Inc.
Oct 23, 2025, 12:47 ET Teaching Strategies Wins 2025 CODiE Award for The Creative Curriculum for Pre-K
The Creative Curriculum for Pre-K has been named the "Best PK/Early Childhood Learning Solution" in the 2025 CODiE Awards.
More news about: Teaching Strategies
Oct 23, 2025, 11:26 ET Community Heritage Financial, Inc. Announces Third Quarter 2025 Financial Results
MIDDLETOWN, Md., Oct. 23, 2025 /PRNewswire/ -- Community Heritage Financial, Inc. (the "Company" or "CHF") (OTC PK: CMHF), the parent company of Middletown Valley Bank ("MVB" or the "Bank"), reported net income of $1.9 million, or $0.66 per diluted share, for the third
More news about: Community Heritage Financial, Inc.
Oct 22, 2025, 18:40 ET Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
versus plasma, enhancing antiviral exposure at the primary infection site.. Following successful completion of Phase 1 safety and PK studies, regulatory approval was granted for Phase 2 initiation in Q3 2025. The Phase 2 program includes:
More news about: Expert Systems, Inc.
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
subcutaneous doses, daily oral doses, weekly oral doses, or placebo. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess change in body weight from baseline, as well as change in
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 12:15 ET CODiE Awards Announce 2025 Winners, Celebrating Innovation and Kicking Off the 40 Years of Excellence in Technology
InStage, InStage Best English Language Arts Instructional Solution for Grades PK - 8 IXL Language Arts, IXL Learning
More news about: CODiE Awards
Oct 21, 2025, 08:33 ET Tieton Cider Works and QFC Collaborate on Exclusive Broadway Rosé Cider - Launch at Flagship Seattle Store
communities and respond to what their shoppers are asking for". Broadway Rosé is available exclusively at QFC's Broadway location beginning this month in 4pk-16oz cans. This launch underscores Tieton Cider Works continued commitment to innovation and partnership, developing private-label and custom packaging
More news about: Tieton Cider Works
Oct 21, 2025, 07:30 ET Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting
Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.03911 Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;202212
More news about: Zimmer Biomet Holdings, Inc.
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
DCR: 66.7%. Favorable PK and PD profiles: Linear PK with half-life of 6-8 days supported every-three-week (Q3W) dosing, with no significant accumulation
More news about: CStone Pharmaceuticals
Oct 19, 2025, 10:30 ET VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04665206) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory mesothelioma. The mesothelioma patients
More news about: Vivace Therapeutics, Inc.